CCRM Nordic has appointed Michael Delahaye as its new Chief Technology Officer (CTO), marking the next stage in the organisation’s growth as it continues to build end-to-end capabilities for advanced therapy medicinal products (ATMPs).
Michael brings more than 15 years of industrial experience in the cell and gene therapy sector. Currently Senior Director of Technical Operations at CCRM Nordic, he has played a key role in establishing the organisation’s current workflows for immuno-oncology and induced pluripotent stem cell (iPSC) therapies, as well as in shaping CCRM Nordic’s viral vector capabilities. His expertise spans the development of scalable, robust manufacturing processes and the use of high-resolution characterisation tools to ensure quality, reproducibility and efficiency in advanced therapy manufacturing.
“CCRM Nordic is building a unique bridge between early-stage innovation and industrial readiness,” said Michael Delahaye. “I’m excited to continue this amazing journey in the role of CTO and to help strengthen the infrastructure and collaborations that bring transformative therapies to patients faster.”
Before joining CCRM Nordic, Michael held senior roles in Biopharmaceuticals R&D at AstraZeneca, led the Viral Vector Industrialization team at the Cell and Gene Therapy Catapult in the UK, and completed an EngD at University College London with multiple industrial collaborations. He also serves as an Adjunct Associate Professor at Linköping University and is a Director of the ATMP Manufacturing Community (AMC) in the UK.
Since relocating to Sweden in 2021, Michael has been inspired by the country’s collaborative ATMP ecosystem. As a board member of ATMP Sweden, he contributes to strengthening knowledge sharing, industry–academic partnerships, and the integration of Swedish innovations into the global ATMP community.
“We’re very pleased to welcome Michael to the leadership team,” said Fredrik Wessberg, CEO of CCRM Nordic. “His experience and vision will be invaluable as we continue building the Nordic region’s capabilities for advanced therapy development and manufacturing.”
Michael succeeds Sarah Callens, who has played a key role in shaping CCRM Nordic’s technical foundations and establishing its strong innovation culture. The organisation extends its sincere thanks to Sarah for her important contributions and leadership during a formative phase of growth.
Michael steps into the role at an exciting time. CCRM Nordic recently advanced its immuno-oncology, iPSC and viral-vector platforms, expanded its analytical capabilities, and is preparing to open its new 3,000 m² CMC development and GMP manufacturing facility at GoCo Health Innovation City in 2026.
With this appointment, CCRM Nordic further strengthens its mission to make the Nordics a leading hub for advanced therapy innovation and translation.